Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.74 USD | -0.72% | -8.36% | -56.33% |
Apr. 23 | Top Premarket Decliners | MT |
Apr. 01 | T2 Biosystems, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2022 | 22.3M | Sales 2023 | 7.19M | Capitalization | 25.42M |
---|---|---|---|---|---|
Net income 2022 | -62M | Net income 2023 | -50M | EV / Sales 2022 | 2.66 x |
Net Debt 2022 | 48.89M | Net Debt 2023 | 33.81M | EV / Sales 2023 | 8.23 x |
P/E ratio 2022 |
-0.12
x | P/E ratio 2023 |
-0.33
x | Employees | 113 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 49.08% |
Latest transcript on T2 Biosystems, Inc.
1 day | -0.72% | ||
1 week | -8.36% | ||
Current month | -8.67% | ||
1 month | -8.05% | ||
3 months | -33.33% | ||
6 months | -54.71% | ||
Current year | -56.33% |
Managers | Title | Age | Since |
---|---|---|---|
John Sperzel
CEO | Chief Executive Officer | 60 | 20-01-07 |
John Sprague
DFI | Director of Finance/CFO | 65 | 18-01-29 |
Roger Smith
CTO | Chief Tech/Sci/R&D Officer | 59 | 13-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Elsbree
BRD | Director/Board Member | 76 | 14-06-30 |
Seymour Liebman
BRD | Director/Board Member | 74 | 16-09-20 |
Robin Toft
BRD | Director/Board Member | 63 | 20-06-13 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 2.74 | -0.72% | 412,212 |
24-04-24 | 2.76 | +1.47% | 330,290 |
24-04-23 | 2.72 | -13.92% | 359,187 |
24-04-22 | 3.16 | +6.76% | 1,363,736 |
24-04-19 | 2.96 | -1.00% | 534,565 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-56.33% | 24.27M | |
+7.71% | 220B | |
+6.25% | 185B | |
+10.60% | 133B | |
+26.73% | 107B | |
-0.57% | 62.91B | |
+15.42% | 53.34B | |
-1.89% | 47.71B | |
-1.91% | 40.29B | |
+11.16% | 39.57B |
- Stock Market
- Equities
- TTOO Stock